Published on 22 Sep 2023 on Zacks via Yahoo Finance
Karuna Therapeutics KRTX announced the submission of a new drug application (“NDA”) with the FDA seeking approval for its lead candidate KarXT, as a potential treatment of schizophrenia.
If approved, Karuna’s KarXT will provide a new treatment option for patients and be the first novel pharmacological approach for schizophrenia treatment in several decades. A commercial launch is expected in second-half 2024.